Jacques Joubert*

Crystal structure of *N*-(adamantan-1-yl)-5-(dimethylamino)naphthalene-1-sulfonamide, $C_{22}H_{28}N_2O_2S$

<https://doi.org/10.1515/ncrs-2019-0404>

Received June 12, 2019; accepted August 25, 2019; available online September 11, 2019

Abstract

$C_{22}H_{28}N_2O_2S$, monoclinic, $P2_1/n$ (no. 14), $a = 9.2516(7)$ Å, $b = 10.5122(8)$ Å, $c = 19.7782(15)$ Å, $\beta = 98.9530(10)^\circ$, $V = 1900.1(2)$ Å³, $Z = 4$, $R_{gt}(F) = 0.0356$, $wR_{ref}(F^2) = 0.1004$, $T = 100(2)$ K.

CCDC no.: 1949154

The molecular structure is shown in the figure (H atoms are omitted for clarity). Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Source of materials

A solution of dansyl chloride (systematic name: 5-(dimethylamino)naphthalene-1-sulfonyl chloride) (1.0 eq.) and amantadine (systematic name: 1-aminoadamantane; 1.0 eq.) in dichloromethane (DCM) (10 mL) was stirred in a sealed tube under microwave irradiation conditions (150 W, 373 K, 150 psi) for 10 min. The solvent was evaporated under reduced pressure and the residue was purified *via* repeated crystallization from ethanol at room temperature to afford the product. Yield 95%; 1H -NMR (400 MHz, $CDCl_3$) δ /ppm = 8.53–8.51 (dd, $J = 6.3$, 2.2 Hz,

Table 1: Data collection and handling.

Crystal:	Colourless shard
Size:	$0.40 \times 0.20 \times 0.06$ mm
Wavelength:	Mo $K\alpha$ radiation (0.71073 Å)
μ :	0.19 mm^{-1}
Diffractometer, scan mode:	Bruker APEX-II DUO, φ and ω
θ_{max} , completeness:	30.5° , >99%
$N(hkl)_{measured}$, $N(hkl)_{unique}$, R_{int} :	60522, 5782, 0.039
Criterion for I_{obs} , $N(hkl)_{gt}$:	$I_{obs} > 2 \sigma(I_{obs})$, 5118
$N(param)_{refined}$:	250
Programs:	Bruker [1], SHELX [2], X-Seed [3, 4], WinGX/ORTEP [5]

1H), 8.32–8.29 (dd, $J = 6.3$, 2.1 Hz, 1H), 8.25–8.23 (dd, $J = 6.3$, 2.1 Hz, 1H), 7.58–7.50 (m, 2H), 7.19–7.17 (dd, $J = 6.4$, 2.1 Hz, 1H), 2.90 (s, 6H), 1.95 (s, 3H), 1.74 (s, 6H), 1.59–1.48 (m, 6H); ^{13}C -NMR (100 MHz, $CDCl_3$) δ /ppm = 151.6, 138.7, 130.0, 129.9, 129.6, 129.0, 128.0, 123.4, 119.2, 115.0, 55.5, 45.5, 43.0, 35.8, 29.5. The title compound (10.0 mg) was dissolved in ethanol, and the solvent was evaporated slowly at ambient conditions. Crystals formed over a period of 3 days.

Experimental details

Single-crystal X-ray intensity data were collected on a Bruker 3-circle Apex II DUO X-ray diffractometer equipped with an INCOATEC $I\mu S$ HB microsource. Data collection and reduction were carried out using the Bruker software package APEX3 [1] using standard procedures. The structure was solved and refined using SHELX-2016 [2] employed within the X-Seed [3, 4] environment. Hydrogen atoms were placed in calculated positions using riding models. ORTEP-3 [5] was used to generate the publication material.

Comment

The title compound was investigated as part of an ongoing study into the development of adamantane conjugated fluorophores that could be used as potential neurobiological fluorescent ligands [6, 7]. The 5-dimethylamino-naphthalene sulfonyl (dansyl) moiety acts as the fluorophore [7, 8]. Continued development of fluorescent adamantane molecules

*Corresponding author: Jacques Joubert, Pharmaceutical Chemistry, School of Pharmacy, University of the Western Cape, Private Bag X17, Bellville, 7535, South Africa, e-mail: jjoubert@uwc.ac.za

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	x	y	z	U _{iso} [*] /U _{eq}
C1	0.14508(12)	0.61431(11)	0.60688(6)	0.0162(2)
H1A	0.111191	0.632305	0.557847	0.019*
H1B	0.189105	0.692946	0.628658	0.019*
C2	0.01439(13)	0.57337(12)	0.64151(7)	0.0205(2)
H2	−0.060563	0.642667	0.636652	0.025*
C3	0.06800(14)	0.54803(15)	0.71770(7)	0.0286(3)
H3A	0.112141	0.626258	0.739896	0.034*
H3B	−0.015560	0.523213	0.740613	0.034*
C4	0.18177(14)	0.44104(16)	0.72476(6)	0.0274(3)
H4	0.216718	0.424695	0.774418	0.033*
C5	0.31256(13)	0.48128(14)	0.69008(6)	0.0212(2)
H5A	0.358414	0.558699	0.712484	0.025*
H5B	0.386789	0.412701	0.694924	0.025*
C6	0.25962(11)	0.50790(10)	0.61396(5)	0.01121(18)
C7	−0.05386(13)	0.45170(12)	0.60823(6)	0.0189(2)
H7A	−0.138054	0.426079	0.630508	0.023*
H7B	−0.090066	0.467374	0.559163	0.023*
C8	0.05972(13)	0.34525(11)	0.61546(6)	0.0188(2)
H8	0.014643	0.266312	0.593145	0.023*
C9	0.19056(13)	0.38521(11)	0.58088(6)	0.0167(2)
H9A	0.157359	0.399610	0.531432	0.020*
H9B	0.264473	0.316370	0.585765	0.020*
C10	0.11244(14)	0.31939(14)	0.69147(7)	0.0266(3)
H10A	0.185234	0.249644	0.696665	0.032*
H10B	0.028897	0.293318	0.714087	0.032*
C11	0.42199(11)	0.79573(10)	0.55727(5)	0.01079(18)
C12	0.40813(12)	0.89081(10)	0.60349(5)	0.01268(19)
H12	0.441036	0.877155	0.650868	0.015*
C13	0.34528(12)	1.00857(10)	0.58094(6)	0.0145(2)
H13	0.338342	1.074640	0.613051	0.017*
C14	0.29411(12)	1.02813(10)	0.51283(6)	0.0138(2)
H14	0.250869	1.107455	0.498261	0.017*
C15	0.30502(11)	0.93113(10)	0.46381(5)	0.01112(18)
C16	0.25293(11)	0.95183(10)	0.39230(5)	0.01220(19)
C17	0.28194(12)	0.86282(11)	0.34488(5)	0.0138(2)
H17	0.252056	0.878057	0.297414	0.017*
C18	0.35586(12)	0.74932(11)	0.36682(6)	0.0143(2)
H18	0.377207	0.689726	0.333641	0.017*
C19	0.39766(12)	0.72296(10)	0.43492(5)	0.01245(19)
H19	0.442377	0.643691	0.448414	0.015*
C20	0.37448(11)	0.81346(10)	0.48535(5)	0.01025(18)
C21	0.02252(14)	1.05688(13)	0.38842(7)	0.0240(3)
H21A	−0.032854	0.995380	0.357334	0.036*
H21B	−0.024275	1.140561	0.381979	0.036*
H21C	0.024324	1.029099	0.435846	0.036*
C22	0.17367(14)	1.10701(12)	0.30315(6)	0.0187(2)
H22A	0.274874	1.113415	0.294488	0.028*
H22B	0.126240	1.190364	0.296221	0.028*
H22C	0.120377	1.045240	0.271502	0.028*
N1	0.38407(10)	0.53698(9)	0.57701(5)	0.01117(16)
H1	0.3742(18)	0.5081(17)	0.5354(9)	0.024(4)*
N2	0.17296(10)	1.06525(9)	0.37360(5)	0.01513(18)
O1	0.54260(9)	0.66769(8)	0.66343(4)	0.01504(16)
O2	0.61620(8)	0.61719(8)	0.55114(4)	0.01376(15)
S1	0.50335(3)	0.65063(2)	0.59084(2)	0.01044(7)

is motivated by their good biological activity, e.g. as nitric oxide synthase inhibitors [6, 9], anti-oxidants [9], *N*-methyl-*D*-aspartate receptor antagonists and voltage-gated calcium channel blockers [7, 9, 10].

The bond lengths, angles and torsion angles of the adamantane ring system and the conjugated 5-dimethylamino-naphtalene sulfonyl moiety are consistent with previously published structures [11–14]. The conformation of the investigated molecule is dependant on the sulfonylamide link, connecting the naphtalene ring and adamantane fragment. Two important torsion angles τ_1 [C6–N1–S1–C11, $-77.19(10)^\circ$] and τ_2 [C12–C11–S1–N1, $115.88(9)^\circ$] describe the conformation of the molecule. Crystal packing analysis reveals that the molecules associate into cyclic dimers. These dimers are connected via a classical intermolecular hydrogen bond, N1–H1...O2i with an H...A distance of 2.38 Å, and an angle of 119.8° . Symmetry code: (i) $-x+1, -y+1, -z+1$. The dimers are uniformly packed in the (*ac*) plane and create alternate stacking in the proximity of the (*ac*) plane.

References

1. Bruker. APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, WI, USA (2018).
2. Sheldrick, G. M.: Crystal structure refinement with SHELXL. *Acta Crystallogr.* **C71** (2015) 3–8.
3. Barbour, L. J.: X-Seed – a software tool for supramolecular crystallography. *J. Supramol. Chem.* **1** (2001) 189–191.
4. Atwood, J. L.; Barbour, L. J.: Molecular Graphics: From science to art. *Cryst. Growth Des.* **3** (2003) 3–8.
5. Farrugia, L. J.: WinGX and ORTEP for Windows: an update. *J. Appl. Crystallogr.* **45** (2012) 849–854.
6. Joubert, J.; van Dyk, S.; Malan, S. F.: Fluorescent polycyclic ligands for nitric oxide synthase (NOS) inhibition. *Bioorg. Med. Chem.* **16** (2008) 8952–8958.
7. Joubert, J.; van Dyk, S. V.; Green, I. R.; Malan, S. F.: Synthesis, evaluation and application of polycyclic fluorescent analogues as *N*-methyl-*D*-aspartate receptor and voltage gated calcium channel ligands. *Eur. J. Med. Chem.* **46** (2011) 5010–5020.
8. Joubert, J.; van Dyk, S. V.; Malan, S. F.: Small molecule fluorescent ligands as central nervous system imaging probes. *Mini-Rev. Med. Chem.* **13** (2013) 682–696.
9. Joubert, J.; van Dyk, S. V.; Green, I. R.; Malan, S. F.: Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents. *Bioorg. Med. Chem.* **19** (2011) 3935–3944.
10. Kaderani, Y. E.; Zindo, F. T.; Kapp, E.; Malan, S. F.; Joubert, J.: Adamantane amine derivatives as dual acting NMDA receptor and voltage-gated calcium channel inhibitors for neuroprotection. *Med. Chem. Commun.* **5** (2014) 1678–1684.
11. Joubert, J.; Samsodien, H.; Baber, Q. R.; Cruickshank, D. L.; Caira, M. R.; Malan, S. F.: Synthesis and structural analysis of novel neuroprotective pentacyclo[5.4.1.02,6.03,10.05,9]undecane- and adamantane-derived propargylamines. *J. Chem. Crystallogr.* **44** (2014) 194–204.

12. Voronin, A. P.; Volkova, T. V.; Ilyukhin, A. B.; Trofimova, T. P.; Perlovich, G. L.: Structural and energetic aspects of adamantane and memantine derivatives of sulfonamide molecular crystals: experimental and theoretical characterisation. *CrystEngComm* **20** (2018) 3476–3489.
13. Bhatt, P.; Govender, T.; Kruger, H. G.; Maguire, G. E. M.: *N*-Benzyl-5-(dimethylamino)-naphthalene-1-sulfonamide. *Acta Crystallogr.* **E67** (2011) o2458–o2459.
14. Zhang, S.; Zhao, B.; Su, Z.; Xia, X.; Zhang, Y.: *N*-(2-Aminoethyl)-5-(dimethylamino)naphthalene-1-sulfonamide. *Acta Crystallogr.* **E65** (2009) o1452.